ADT Pharmaceuticals, LLC

Orange Beach, AL

UEI
YL5LNM35E194
CAGE
7BX76
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
31691 Shoal Water Dr, Orange Beach, AL 36561, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Topic 386: novel orally bioavailable PDE -catenin inhibitor concentrates in lung for cancer chemoprevention 75N91019C00020 National Cancer Institute (NIH) $299,963

Grant awards

Award Agency Obligated Awarded
Oral formulation for novel inhibitor of RAS driven cancers R43CA217502 National Cancer Institute (NIH) $301,330
Novel RAS inhibitor prodrug for colorectal cancer R43CA206807 National Cancer Institute (NIH) $290,843
A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer R43CA189613 National Institutes of Health $224,630

Quick answers

Is ADT Pharmaceuticals, LLC registered in SAM.gov?

Yes. ADT Pharmaceuticals, LLC's SAM.gov registration is active through November 15, 2026.

What is ADT Pharmaceuticals, LLC's most recent federal award?

ADT Pharmaceuticals, LLC's most recent federal contract award is Topic 386: novel orally bioavailable PDE -catenin inhibitor concentrates in lung for cancer chemoprevention (75N91019C00020), from National Cancer Institute (NIH), on September 16, 2019.

On GovTribe

See ADT Pharmaceuticals, LLC's full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login